ScienceDex / Researcher record
Sean Wasserman
- Program Leader
- Early Career
NIH Funding · FY2026
Award data coverage
One fiscal year is available for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2026): $1.2M in linked award amounts across 3 award records · Award-linked rank #16621.
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2026 · selected3 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 80311364Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2026 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2026 award records by amount
NIH award records listing Sean Wasserman as a PI. Multi-PI records show the full award amount for context.
- 4U01AI170426-05U01Co-investigatorPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$526.3Kaward amount
- 3U01AI170426-05S2U01Co-investigatorPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$365.4Kaward amount
- 3U01AI170426-05S1U01Co-investigatorPRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosisBrigham and Women's Hospital · Internal Medicine (investigator's affiliation)$331Kaward amount
Award organization
Organizations that administered FY2026 awards listing Sean Wasserman as a PI.
FY2026 award administered by Brigham and Women's Hospital (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2026First NIH AwardBrigham and Women's Hospital
- 2026$500K Cumulative Funding
- 2026$1M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Sean Wasserman.